Vivimed Labs Limited has received official confirmation from both BSE Limited and the National Stock Exchange of India Limited (NSE) regarding the revocation of trading suspension for its equity shares. The announcement marks a significant milestone for the pharmaceutical company and its shareholders who have awaited the resumption of trading activities.

Official Revocation Details

The stock exchanges issued their official communications on December 10, 2025, confirming the decision to lift the trading suspension. The revocation follows the company's successful compliance with regulatory requirements and addresses previous non-compliances under SEBI (LODR) Regulations, 2015.

Regulatory Framework and Compliance

The revocation operates under the provisions of SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. This master circular replaced the erstwhile SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, providing the regulatory framework for such revocations.

Vivimed Labs Limited has diligently worked to address all regulatory concerns and has committed to maintaining compliance standards going forward. The company expressed gratitude to both exchanges and shareholders for their support during the challenging compliance period.

Market Resumption Process

Trading in Vivimed Labs Limited equity shares will resume through a structured process designed to ensure orderly market reopening. The scrip will participate in the Special Pre-open Session for IPOs & Relisted Scrips on December 18, 2025, before regular trading commences.

This special session helps facilitate price discovery and provides market participants with an organized mechanism to resume trading activities. The company's shares will trade in the T group under the Trade for Trade category, which requires delivery-based settlements.

Company Commitment and Outlook

Vivimed Labs Limited has assured stakeholders of its continued commitment to regulatory compliance, transparency, and sustained shareholder value creation. The company views this revocation as a turning point that reinstates liquidity for shareholders and enables proper price discovery mechanisms.

The pharmaceutical company, with its registered office in Bidar, Karnataka, operates in the healthcare sector and has worked systematically to resolve compliance issues. With trading resumption imminent, the company looks forward to renewed market participation and continued business operations under proper regulatory oversight.

Vivimed Labs Limited successfully conducted its Extraordinary General Meeting (EGM) on December 10, 2025, where shareholders voted on a critical special resolution regarding the company's financial restructuring. The meeting, held at 3:00 p.m. through video conferencing and other audio-visual means, addressed the application to initiate pre-packaged insolvency resolution process under the Insolvency and Bankruptcy Code, 2016.

Voting Results and Shareholder Participation

The special resolution received overwhelming support from shareholders, with detailed voting results demonstrating strong confidence in the proposed restructuring approach:

The voting process included both remote e-voting and venue-based electronic voting. Remote e-voting attracted 76 shareholders who cast 2,11,53,107 votes, representing 99.64% of total valid votes. Additionally, 16 shareholders participated through venue e-voting at the EGM, contributing 12,877 votes.

E-Voting Process and Timeline

Vivimed Labs Limited provided comprehensive e-voting facilities to ensure maximum shareholder participation. The remote e-voting window remained open from 9:00 a.m. on December 7, 2025, until 5:00 p.m. on December 9, 2025. The company appointed Mr. N.V.S.S. Suryanarayana Rao, a practicing Company Secretary, as scrutinizer to oversee the entire voting process and ensure compliance with regulatory requirements.

Category-wise Voting Breakdown

The voting results showed strong support across different shareholder categories:

Notably, the promoter and promoter group demonstrated complete support for the resolution, while public institutions also showed strong backing with 99.60% votes in favor.

Regulatory Compliance and Documentation

The EGM was conducted in full compliance with Section 108 of the Companies Act, 2013, and Rule 20 of the Companies (Management and Administration) Rules, 2014. The company also adhered to Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The scrutinizer submitted detailed reports on December 10, 2025, confirming the validity of the voting process and results.

Meeting Logistics and Record Date

The company set December 3, 2025, as the record date for determining eligible shareholders. As of this date, Vivimed Labs Limited had 49,959 total shareholders. The deemed venue for the EGM was the company's registered office at Plot No. 78/A, Kolhar Industrial Area, Bidar-585403, Karnataka, though the meeting was conducted entirely through digital means due to regulatory guidelines.